C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6.83 HKD -2.01% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Cutia Therapeutics
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cutia Therapeutics
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
C
Cutia Therapeutics
HKEX:2487
Net Change in Cash
ÂĄ7.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Change in Cash
-ÂĄ5.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Change in Cash
ÂĄ381.7m
CAGR 3-Years
-37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Change in Cash
-ÂĄ1.4B
CAGR 3-Years
N/A
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Change in Cash
ÂĄ362.5m
CAGR 3-Years
-50%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Net Change in Cash
-ÂĄ705.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cutia Therapeutics
Glance View

Market Cap
2.1B HKD
Industry
Biotechnology

Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.

Intrinsic Value
11.5 HKD
Undervaluation 41%
Intrinsic Value
Price
C

See Also

What is Cutia Therapeutics's Net Change in Cash?
Net Change in Cash
7.3m CNY

Based on the financial report for Dec 31, 2023, Cutia Therapeutics's Net Change in Cash amounts to 7.3m CNY.

What is Cutia Therapeutics's Net Change in Cash growth rate?
Net Change in Cash CAGR 1Y
-97%

Over the last year, the Net Change in Cash growth was -97%.

Back to Top